- Production
of more than 3.2 million high-quality cannabis clones is expected once
initial cultivation facility is complete
- Global
cannabis market projected to reach nearly $155 billion by 2025
- Expanded
sales license from Health Canada received, permitting sale of genetic
material
The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Canadian
licensed producer of premium cannabis products, plans to expand its product
line by selling a selection of its premium, high-quality cannabis in clone and
seed form to customers both at home and abroad. Company Co-CEO Tom Flow
announced the venture in a news release that highlights Flowr’s emphasis on
growing only premium cannabis using non-irradiated production methods that
generate high crop yields at low operating costs.
“This is an exciting and potentially very big market for
Flowr that is a natural extension of our high-yield, high-quality approach to
cultivation,” Flow stated in the release (http://ibn.fm/XNq09). “Growing great cannabis starts
with great genetics and clean healthy plants, something few companies are able
to provide. As we ramp up production, we believe Flowr will be able to
offer the select cultivars we use to produce our premium cannabis to
cultivators globally.”
Canada opened up recreational cannabis to adult users in
October 2018 and has since released new regulations governing cannabis-infused
edibles and beverages, along with cannabis concentrates. Those products are set
to be legalized in mid-October 2019. Most Canadian provinces allow adults to
grow up to four cannabis plants per household, which opens the door to yet
another market, although many budding cannabis home cultivators are unsure
where to begin. However, one man in Alberta, Canada, featured in a CBC
article (http://ibn.fm/BMF87),
has launched his own website offering tips and info for cannabis beginners,
pointing out that “quality genetics” is “the secret to growing good cannabis.”
Flowr’s flagship facility, an approximately
85,000-square-foot campus on seven acres in Kelowna, British Columbia, is
engineered to grow premium cannabis in rooms that meet pharmaceutical industry
production standards for cleanliness. This, along with exacting protocols
designed by the Flowr team, enables Flowr to grow cannabis that meets Health
Canada’s stringent standards without treating it with the taste- and
smell-killing gamma irradiation that most other producers use to clean their
product. A majority of current Canadian cannabis consumers are willing to pay
more for premium products that are grown and produced under the country’s
federal regulations, according to Deloitte’s 2018 Cannabis Report (http://ibn.fm/jLPg3).
Flowr Corporation, which in December 2018 received an
expanded sales license from Health Canada permitting it to sell genetic
material, expects that its highly efficient cultivation process will allow it
to produce more than 3.2 million high-quality clones on an annualized basis
once its initial cultivation facility is completed by the end of the third
quarter of 2019. These clones will be incremental to Flowr’s cultivation
process, which means that this new revenue stream will be produced in addition
to what the company actually needs for its retail and medical production.
Flow indicated that opportunities for Flowr exist in four
key markets: Canadian license holders seeking high-quality genetics as they
expand production; micro-cultivators, a new Health Canada license subclass that
can operate small “craft” cultivation facilities; producers in international
markets; and individuals purchasing through provincial or licensed private
retailers for personal use (home growers). The recent addition of Deron Caplan,
the first person in North America to earn a doctorate in philosophy with
research focused on cannabis production, as Flowr’s director of plant science
reinforces the company’s commitment to the pursuit of excellence in cannabis
cultivation techniques and genetics (http://ibn.fm/v4AfG).
Flowr also announced that its premium cannabis products are
now for sale through licensed private retailers in Manitoba, which expands the
company’s reach to five provinces (http://ibn.fm/Rj61Z). Flowr previously announced supply
agreements with provincial authorities in British Columbia, Nova Scotia and
Ontario; sales through a private dispensary in Saskatchewan; and entry into a
medical cannabis supply agreement with Shoppers Drug Mart (http://ibn.fm/YLoix).
According to Stratistics MRC, the global cannabis market
accounted for $10.39 billion in 2017 sales and is expected to reach $154.82
billion by 2026, growing at a compound annual growth rate of 35 percent during
the forecast period. Some of the key factors propelling the market growth are
the medicinal properties of cannabis, increasing legalization of cannabis and
advances in genetic development and intellectual property related to
cannabis (http://ibn.fm/EmIQu).
Flowr’s purpose-built cultivation facilities, developed with
proprietary, patent-pending systems, are designed to deliver yields targeted at
425 grams per square foot by the end of 2022, which is three-times more
efficient than the industry average of approximately 150 grams per square foot.
By optimizing yield, Flowr may produce significantly more cannabis flower on a
smaller footprint than other producers, thus generating significantly higher
revenue per square foot and keeping costs much lower, leading to greater
margins.
For more information, visit the company’s website at www.Flowr.ca
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment